Clinical development of exelon (ena-713): the adena® programme

Journal of Drug Development and Clinical Practice

Volumn 8, Issue 2, 1996, Pages 117-122

  Anand, R ^a   Gharabawi, G ^a  

^a Sandoz Pharma Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; RIVASTIGMINE;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CHOLINESTERASE INHIBITION; CLINICAL TRIAL; DEMENTIA; DRUG EFFICACY; DRUG ELIMINATION; DRUG SELECTIVITY; DRUG TOLERABILITY; FEMALE; HIPPOCAMPUS; HUMAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0029778789     PISSN: 13579215     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Kennedy JS, Polinsky RJ, Johnson B, et al. Plasma and CSF pharmacokinetic/pharmacodynamic profiles of SDZ ENA-713 in man. Poster presented at American Collegium Neuropsychopharmacologium meeting, San Juan, Puerto Rico, December 1995.
2. Enz A, Amstutz R, Bodeke H, et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. In: Cuello AC, editors. Cholinergic function and dysfunction, progress in brain research Vol 98. Amsterdam: Elsevier Science, 1993:431-438.
3. Rosen WG, Mohs RC, Davis KL. AmJ Psychiatry 1984;141:1356-1364.
4. Knopman DS, Knapp MJ, Gracon SJ, Davis CS. Neurology- 1994;44:2315-2321.
5. Reisberg B, Ferris SH. CIBIC-Plus Interview Guide. 1994.
6. Dejong R, Osterlund OW, Roy GW. Clin Ther 1989;! 1:545-554.